Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.

Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.
复制标题

DOI:
10.1002/ijc.25993
复制
发表时间:
2012-01-01
影响因子:
6.4
通讯作者:
Lu, Junxuan
Lu, Junxuan
中科院分区:
医学1区
文献类型:
--
作者:
Zhang, Yong;Kim, Kwan-Hyun;Zhang, Wei;Guo, Yinglu;Kim, Sung-Hoon;Lu, Junxuan

文献摘要

参考文献

被引文献

相似文献

Androgen receptor (AR) signaling is crucial for the genesis and progression of prostate cancer (PCa). We compared the growth responses of AR(+) LNCaP and LNCaP C4-2 vs. AR(−) DU145 and PC-3 PCa cell lines to galbanic acid (GBA) isolated from the resin of medicinal herb Ferula assafoetida and assessed their connection to AR signaling and cell cycle regulatory pathways. Our results showed that GBA preferentially suppressed AR(+) PCa cell growth than AR(−) PCa cells. GBA induced a caspase-mediated apoptosis that was attenuated by a general caspase inhibitor. Subapoptotic GBA down-regulated AR protein in LNCaP cells primarily through promoting its proteasomal degradation, and inhibited AR-dependent transcription without affecting AR nuclear translocation. Whereas docking simulations predicted binding of GBA to the AR ligand binding domain with similarities and differences with the AR antagonist drug bicalutamide, LNCaP cell culture assays did not detect agonist activity of GBA. GBA and bicalutamide exerted greater than additive inhibitory effect on cell growth when used together. Subapoptotic GBA induced G1 arrest associated with an inhibition of cyclin/CDK4/6 pathway, especially cyclin D1 without the causal involvement of CDK inhibitory proteins P21Cip1 and P27Kip1. In summary, the novelty of GBA as an anti-AR compound resides in the distinction between GBA and bicalutamide with respect to AR protein turnover and a lack of agonist effect. Our observations of anti-AR and cell cycle arrest actions plus the anti-angiogenesis effect reported elsewhere suggest GBA as a multi-targeting drug candidate for the prevention and therapy of PCa.
DOI: 10.1038/nm972
发表时间: 2004-01-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Chen, CD;Welsbie, DS;Sawyers, CL
通讯作者: Sawyers, CL
DOI: 10.1093/nar/gkm198
发表时间: 2007
影响因子: 14.9
作者:
Li TH;Zhao H;Peng Y;Beliakoff J;Brooks JD;Sun Z
通讯作者: Sun Z
DOI: 10.1093/emboj/cdf406
发表时间: 2002-08-01
期刊: EMBO JOURNAL
影响因子: 11.4
作者:
Lin, HK;Wang, L;Chang, CS
通讯作者: Chang, CS
DOI: 10.1158/1535-7163.mct-06-0231
发表时间: 2007-03-01
影响因子: 5.7
作者:
Guo, Junming;Jiang, Cheng;Lu, Junxuan
通讯作者: Lu, Junxuan